References
- He, J. and Whelton, P.K. (1997) Epidemiology and prevention of hypertension. Med. Clin. North Am., 81, 1077-1097. https://doi.org/10.1016/S0025-7125(05)70568-X
- Whelton, P.K. (1994) Epidemiology of hypertension. Lancet, 344, 101-106. https://doi.org/10.1016/S0140-6736(94)91285-8
- Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. and He, J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet, 365, 217-223. https://doi.org/10.1016/S0140-6736(05)17741-1
- Brunner, H.R. (2006) Olmesartan medoxomil: current status of its use in monotherapy. Vasc. Health Risk Manage., 2, 327-340. https://doi.org/10.2147/vhrm.2006.2.4.327
- Fletcher, A.E., Palmer, A.J. and Bulpitt, C.J. (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl., 12, S43-S47.
- Vleeming, W., van Amsterdam, J.G., Stricker, B.H. and de Wildt, D.J. (1998) ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf., 18, 171-188. https://doi.org/10.2165/00002018-199818030-00003
- Warner, G.T. and Jarvis, B. (2002) Olmesartan medoxomil. Drugs, 62, 1354-1356. https://doi.org/10.2165/00003495-200262090-00009
- Mizuno, M., Sada, T., Ikeda, M., Fukuda, N., Miyamoto, M., Yanagisawa, H. and Koike, H. (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 285, 181-188. https://doi.org/10.1016/0014-2999(95)00401-6
- OECD/OCDE. (1997) OECD guidelines for the testing of chemicals (No. 471), Bacterial Reverse Mutation Test, pp. 1-11.
- Norwood, D., Branch, E.I., Smith, B. and Honeywell, M. (2002) Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast., 27, 611-618.
- Schwocho, L.R. and Masonson, H.N. (2001). Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol., 41, 515-527. https://doi.org/10.1177/00912700122010393
- Puchler, K., Nussberger, J., Laeis, P., Wittem, P.U. and Brunner, H.R. (1997) Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist in saltrestricted hypertensive patients. J. Hypertens., 15, 1809-1812. https://doi.org/10.1097/00004872-199715120-00094
- Brambilla, G. and Martelli, A. (2006) Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat. Res., 612, 115-149. https://doi.org/10.1016/j.mrrev.2005.12.002